Medication-error prevention
Insulin glargine: verify the product before the injection
An instruction that is safe for one insulin may be wrong for another. The cited Lantus label says not to dilute or mix it with any insulin or solution. Recognizing the product and device is therefore part of the clinical decision, not a cosmetic detail.
Sources checked October 6, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Read the name and concentration every time
The cited label warns about accidental insulin-product mix-ups and instructs patients to check the label before every injection. A familiar pen color or storage position cannot replace the product name and concentration.
Confirm the device, route and prescribed units. Do not transfer a technique from another insulin, concentration or device without checking the current instructions. A dose written in units is not permission to improvise a volume or delivery method.
Do not extend a mixing rule
Some learners recall a mixing sequence for other insulin products and apply it too broadly. Lantus has a specific restriction: do not dilute or mix with another insulin or solution.
If a proposed preparation combines Lantus and another insulin, stop and clarify the administration plan. Correct arithmetic does not remove the product incompatibility or authorize a combined syringe.
Treat changes as monitored transitions
The label calls for changes to an insulin regimen under close medical supervision with increased glucose-monitoring frequency. Product, strength, injection site and meal-related changes can affect glycemic control.
Do not offer a conversion dose from a sparse case. Recover the full prior and new regimens and the monitoring plan, and distinguish a prescription change from a patient's independent substitution.
Connect technique with hypoglycemia risk
The label discusses lipodystrophy and localized cutaneous amyloidosis. Repeated injection into affected tissue can be associated with hyperglycemia, while a sudden switch to unaffected tissue can be associated with hypoglycemia.
Teach site rotation using the specific product instructions and a supervised plan when longstanding technique changes. Checking technique is useful, but it should not distract from urgent assessment of a patient with severe hypoglycemia symptoms.
A worked case
A learner proposes putting a prescribed Lantus dose and a rapid-acting insulin dose into one syringe to reduce injections. Both dose calculations are correct. What fails the safety check?
- Identify Lantus as the actual insulin, not simply a generic category of clear insulin.
- Apply the cited restriction against mixing with another insulin or solution.
- Clarify the separate administration plan; do not approve the combined preparation from correct dose arithmetic.
Answer: The product-specific no-mixing restriction, not the arithmetic, determines the answer.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Can Lantus be mixed because both products are clear?
No. The cited label says not to dilute or mix Lantus with another insulin or solution.
2. Is pen color enough to confirm the product?
No. Check the exact insulin label before injection.
3. Should a regimen change be made without additional monitoring?
No. The label calls for close medical supervision and increased glucose monitoring.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.